Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: GYRE THERAPEUTICS is not explicitly mentioned in the provided information; however, related entities in the biotech field include Harmony Biosciences and Neurocrine Biosciences, which have received mixed analyst ratings recently. Additionally, Continuity Biosciences' acquisition of Focal Medical aims to improve drug delivery for cancer treatments, reflecting ongoing innovations in the industry.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
